EUVIMEDEUVIMED entdecken
Crossref

Disproportionality analysis of cardiac adverse events associated with lenvatinib using the Japanese Adverse Drug Event Report database

Yuko Kanbayashi iD, Sakura Kobayashi, Asuka Kojima, Haruka Wakabayashi, Tadashi Shimizu, Mayako Uchida

British Journal of Clinical Pharmacology · 2024

DOI: 10.1111/bcp.16237 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Yuko Kanbayashi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Education and Research Center for Clinical Pharmacy, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Takatsuki, Japan. Hauptthemen laut MEDLINE: Quinolines, Phenylurea Compounds, Adverse Drug Reaction Reporting Systems, Databases, Factual. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: No funding was received for this study, Taiho Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

This study was conducted to examine disproportionality, times to onset, incidence rates and outcomes of lenvatinib‐associated cardiac adverse events (AEs) using the Japanese Adverse Drug Event Report database.

Methods

We analysed data for the period between April 2004 and May 2023. Data on cardiac AEs were extracted and the relative disproportionality of AEs was estimated using reporting odds ratios (RORs). Furthermore, Weibull distribution parameters were calculated.

Results

Of the 2 230 863 reports analysed, we identified 7684 reports of AEs associated with lenvatinib, including 317 cardiac AEs. Signals were detected for eight cardiac AEs: hypertension, cardiac failure, myocarditis, myocardial infarction, immune‐mediated myocarditis, cardiomyopathy, angina unstable and cardiotoxicity. Among these, fatal outcomes were observed for cardiac failure, myocarditis and myocardial infarction. Histograms of median times to onset for the eight detected cardiac AE signals showed that AEs occurred at a median of 3.5–134.5 days after lenvatinib administration. The Weibull distributions showed that cardiac failure occurred early after administration (early failure type), myocarditis occurred in a dose‐dependent manner (wearout failure type), and myocardial infarction occurred constantly throughout the exposure period (random failure type).

Conclusions

We focused on cardiac AEs associated with lenvatinib as post‐marketing AEs. Serious outcomes can arise after lenvatinib administration. Patients should be monitored for signs of onset of these AEs not only at the start of administration, but also over an extended period.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

QuinolinesPhenylurea CompoundsAdverse Drug Reaction Reporting SystemsDatabases, FactualHumansJapanMaleFemaleAgedMiddle AgedAdultCardiotoxicityAged, 80 and overDose-Response Relationship, DrugIncidenceYoung AdultHeart DiseasesAntineoplastic AgentsProtein Kinase InhibitorsAdolescentEast Asian People

Stichwörter der Autor:innen

Japanese Adverse Drug Event Report databasecardiac adverse eventlenvatiniboutcometime to onset

Substanzen

lenvatinibQuinolinesPhenylurea CompoundsAntineoplastic AgentsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Education and Research Center for Clinical Pharmacy, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
  • Department of Education and Research Center for Pharmacy Practice, Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kyotanabe, Japan.
  • School of Pharmacy, Hyogo Medical University, Kobe, Japan.

ORCID-Profile: Yuko Kanbayashi

Förderung

  • No funding was received for this study
  • Taiho Pharmaceutical

Zitieren

APA

Kanbayashi, Y., Kobayashi, S., Kojima, A., Wakabayashi, H., Shimizu, T., & Uchida, M. (2024). Disproportionality analysis of cardiac adverse events associated with lenvatinib using the Japanese Adverse Drug Event Report database. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16237

Vancouver

Kanbayashi Y, Kobayashi S, Kojima A, Wakabayashi H, Shimizu T, Uchida M. Disproportionality analysis of cardiac adverse events associated with lenvatinib using the Japanese Adverse Drug Event Report database. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.16237

BibTeX
@article{Kanbayashi2024,
  author = {Kanbayashi, Yuko and Kobayashi, Sakura and Kojima, Asuka and Wakabayashi, Haruka and Shimizu, Tadashi and Uchida, Mayako},
  title = {Disproportionality analysis of cardiac adverse events associated with lenvatinib using the Japanese Adverse Drug Event Report database},
  journal = {British Journal of Clinical Pharmacology},
  year = {2024},
  doi = {10.1111/bcp.16237}
}
Kostenlos starten →